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Abstract: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become in-
creasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the 
initial step. The doubts raised by the recently published trials of revascularization strategies have led to a renewed 
focus on pharmacological strategies promoting blood pressure control and renal protection. It is essential to further 
elucidate the pathophysiological mechanisms underlying hypoperfusion induced renal microvascular dysfunction 
with subsequent tissue injury and fibrogenesis. The role of renin angiotensin aldosterone system as a mediator of 
the main pathophysiological consequences of ischemic nephropathy is well known. However, more recent experi-
mental evidence on the adrenergic system and intrarenal tubular feedback mechanisms has stimulated new interest 
towards a multi-target therapeutic approach. This review focuses on the pharmacology of the principle therapeutic drug classes currently 
used in the treatment of atherosclerotic renal artery stenosis with an analysis of their metabolic aspects and use in clinical practice based 
on evidence from clinical trials.  
Keywords: Chronic kidney disease, renal artery stenosis, ischemic nephropathy, ACE-inhibitors, angiotensin II receptors-blockers, direct 
renin inhibitors. 
INTRODUCTION  
 Chronic kidney disease (CKD) is a major, worldwide health 
problem. The most rapidly growing age group of the population 
reaching end stage renal disease (ESRD) are those over 65 years of 
age [1]. Ischemic nephropathy (IN) associated with atherosclerotic 
renal artery stenosis (ARAS) is thought to account for 5-10% of 
incident ESRD cases [2, 3]. However, it may be an under diagnosed 
clinical entity and the prevalence is probably higher [3]. The term 
ischemic nephropathy has been used to refer to kidney injury in a 
variety of acute and chronic settings. For the purposes of this re-
view, this term will encompass the reduction in glomerular filtra-
tion rate (GFR) associated with marked decrease in renal perfusion 
pressure in ARAS; the presence of IN implies hemodynamically 
significant ARAS activating neurohormonal systems involved in 
downstream effects leading to kidney injury and atrophy [4]. ARAS 
is generally associated with systemic atherosclerosis and conse-
quently, with significant cardiovascular morbidity and mortality [5-
11]. Early reports of renal artery revascularization for the treatment 
of ARAS demonstrated benefit on control of blood pressure and 
kidney function [1, 12-15]. However, more recent clinical trials 
have focused on additional well-defined clinical endpoints includ-
ing cardiovascular events and accepted contemporary renal end-
points such as need for renal replacement therapy [16-18]. The 
CORAL study compared endovascular stenting and optimal medi-
cal therapy showing no benefit of stenting when added to medical 
therapy in improving cardiovascular and renal outcomes. The aim 
of medical therapy goal was to optimize all modifiable cardiovascu-
lar and renal risk factors including hypertension, hyperlipidemia, 
glycemic control, antiplatelet therapy and smoking cessation. A 
unique aspect of this trial was that antihypertensive therapy cen-
tered on RAAS blockade [16]. RAAS plays an essential role in both 
kidney metabolic demand and cardiovascular morbidity [19]. Drugs 
that block the RAAS have been shown to be helpful in preventing 
downstream effects of ARAS in the kidney and cardiovascular  
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systems [20]. In this review, we will explore the pharmacologic 
aspects of drugs that act on the RAAS and their use in the clinical 
management of patients with ARAS and associated CKD. 
RAAS ROLE IN CHRONIC ISCHEMIC NEPHROPATHY 
AND EXPERIMENTAL BASIS FOR RAAS BLOCKADE  
 Since ARAS was identified as a possible reversible cause of 
hypertension and kidney impairment, the interest in the study of this 
condition has grown [21]. Recent evidence of RAAS inhibitors 
efficacy in ARAS management compared to an interventional ap-
proach warrants further scrutiny from a pathophysiological stand-
point. 
 The comprehension of underlying mechanisms of RAAS effects 
has a long history begun with Goldblatt rats’ models of two-kidney 
one-clip renal arteries. These experiments demonstrated the causal 
relationship between renal artery stenosis and the development of 
hypertension as a three stage process [22]. RAAS is clear link be-
tween renal artery obstruction and renovascular hypertension. Its 
activation is “traditionally” triggered by a decreased afferent arte-
riola shear stress, which induces Renin release with subsequent 
Angiotensin II (AngII) and Aldosterone production [21]. The re-
sults are a progressive vasoconstriction of efferent arteriole with an 
increase of intraglomerular pressure, salt and water retention with 
consequent volume expansion and an eventual increase of systemic 
blood pressure. At this stage, clip removal or ACE inhibitors (ACE-
Is) administration reverse high blood pressure. The second phase, 
after five to eight weeks from clipping, is characterized by further 
salt-retention and volume expansion, while RAAS begins to be 
down regulated. Clip removal or ACE-Is are still able to restore 
normal blood pressure with studies showing that, AngII is the main 
vasoactive mediator during this phase. Finally, in the third phase, 
after nine weeks from clipping, Renin and AngII activity drops 
down. Clip removal is no longer effective and only ACE-Is at 
higher doses can decrease blood pressure [22].  
 On the other hand, while the cause-effect link between renal 
artery narrowing and hypertension was well illustrated in this 
model, the relation between renal artery occlusion and irreversible 
kidney dysfunction is different and not so well defined. In fact not 
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all ARAS, even when severe, results in a progressive decline in 
GFR. This suggests that the link between ARAS and CKD is more 
complex than a simple mechanical obstruction, as suggested by the 
differing responses seen following relief of vascular obstruction in 
fibromuscular dysplasia and ARAS. In fibromuscular dysplasia, 
restoration of flow regularly produces an improvement in both 
renovascular hypertension and rate of GFR decline, whereas no 
RCTs have clearly demonstrated the same benefit in ARAS [23, 
24]. In this setting, the greater the degree chronicity and severity of 
the vascular occlusion, the less the likely it is that the kidney func-
tion will improved after revascularization [25]. In fact, the persis-
tence of a chronic tissue hypoxia activates pro-inflammatory and 
pro-fibrotic pathways with consequent microvessels rarefaction and 
interstitial fibrosis [26, 27].  
 The term “ischemic nephropathy” should suggest that kidney 
failure is mainly due to hypoxic hypoperfusion, but the real contri-
bution of low oxygen delivery to renal injury in ARAS is contro-
versial [28]. Renal metabolic demand is much lower than renal 
blood flow (around 10%) and not all parenchyma areas are equally 
vulnerable to decreased perfusion pressure [26]. Interestingly, stud-
ies by blood oxygen level dependent magnetic resonance (BOLD-
MR) have demonstrated that mild or moderate reduction in renal 
perfusion pressure (up to 40%) and in renal blood flow (up to 30%) 
does not induce severe renal cortex hypoxia. Only a "critical" 
stenosis (70 to 80%) induces cortical hypoxia and relevant pressure 
gradient [29]. Therefore, hypoxia is not the sole determinant, as 
other factors such as hypertension, atherosclerosis and endothelial 
dysfunction are also involved in inducing parenchymal vascular 
injury and chronic renal impairment [30]. Indeed, the above three-
stage process has been studied extensively when renal artery lesions 
are severe, whilst the role of less severe flow reductions in inducing 
renal dysfunction is not well-defined [31]. Textor proposed that the 
contemporary interaction between renal hypoperfusion and persis-
tent RAAS activation accelerates atherosclerosis progression [32]. 
Alternatively, atherosclerosis could aggravate the process, leading to 
persistent GFR reduction by triggering and amplifying the activation 
of several pro-inflammatory and pro-fibrotic pathways [33, 34]. In 
ARAS, the renal vascular endothelium is exposed to multiple injuries, 
as a consequence of the simultaneous presence of atherosclerotic 
inflammation, hypertension, RAAS-induced vasoconstriction and 
reduced bioavailability of the vasodilator nitric oxide [35].  
 In turn, endothelial dysfunction reduces vascular proliferative 
capacity, migratory properties and blunts protection from inflam-
matory cell infiltration [36, 37]. The consequence is a progressive 
injury that starts with tubulointerstitial changes and continues with 
glomerulosclerosis, tubulointerstitial fibrosis and/or vascular scle-
rosis, leading to irreversible scarring [38]. Recent evidence suggests 
that RAAS activation is the central feature of all these interactions, 
by mediating all hemodynamic intra- and extra-renal consequences 
of ARAS [39, 40]. 
 It has also been clearly demonstrated that RAAS inhibitors have 
reno-protective and antiproteinuric effects, due to their action in 
regulating intra-glomerular pressure, reducing arterial pressure and 
dilating efferent arterioles [41]. Moreover, studies in both animal 
and human models have confirmed cross-talk between RAAS acti-
vation and atherosclerosis [41]. In fact, AngII is able to stimulate 
intracellular signaling pathways, which promote enzymatic produc-
tion of oxygen-derived free radicals (ROS), oxidation of LDL, en-
dothelial impairment, matrix degradation and thrombosis [42-44]. 
Thus, AngII promotes post-ischemic injuries in hypertensive kidney 
by inducing oxidative stress [45, 46]. 
 As a consequence, the antioxidant effects of RAAS blockade 
could be important in preventing chronic IN. However, while acute 
AngII effects in renovascular hypertension are well known [47, 48], 
the long-term consequences of increased levels of AngII (and re-
lated oxidative stress) for renal function in the 2-Kidneys 1-Clip 
model have not been extensively studied. Nevertheless, there is 
experimental evidence that the renal damage due to prolonged arte-
rial narrowing is mainly due the oxidative stress elicited by the 
increased production of AngII [49]. Therefore, the observed benefi-
cial effects of RAAS blockade are due in part to improvement in 
renal hemodynamic, and in part to beneficial effects on oxidative 
stress endothelial function, systemic inflammation, and fibrosis, as 
reported by studies comparing RAAS inhibitors with other anti-
hypertensive drugs [50, 51]. 
PHARMACOLOGICAL ASPECTS OF RAAS BLOCKADE  
 RAAS is a hormonal system exerting an essential role in regula-
tion of blood pressure, extracellular volume and tissue perfusion. 
Renin secretion is stimulated by decreased perfusion pressure, in-
creased NaCl delivery and adrenergic hyperactivity [52]. Renin 
starts the first step of the RAAS by cleaving the N-terminal portion 
of Angiotensinogen, to produce the biologically inert decapeptide 
AngI. Angiotensinogen is produced by liver, although its mRNA 
can be detected in many other tissues including kidney, brain, heart, 
vascular, adrenal gland, ovary, placenta, and adipose tissue and its 
circulating levels are constitutively stable [53]. The second step is 
AngII synthesis through the hydrolyzation of AngI by Angiotensin-
converting enzyme (ACE), a membrane-bound exopeptidase local-
ized on the plasma membranes of various cell types. AngII is the 
primary active product of RAAS and the most important product, 
stimulating AngII specific receptors and Aldosterone release [54, 
55]. 
 However, recent evidences have added new insights into the 
RAAS. Firstly, it has been discovered that AngII has at least 4 An-
giotensin receptor subtypes. The type 1 (AT1) receptor predomi-
nantly mediates established and “canonical” physiological effects, 
such as vasoconstriction, increased blood pressure, increased car-
diac contractility, vascular and cardiac hypertrophy, stimulation of 
Aldosterone synthesis, renal tubular sodium reabsorption and inhi-
bition of renin release. The AT1 receptor also mediates effects of 
AngII on cell growth and proliferation, inflammatory responses, 
oxidative stress and establishing the ACE/AngII/AT1 receptors axis 
[56]. The type 2 (AT2) receptors have different effects. Indeed, 
AT2 receptors stimulation exert antiproliferative, pro-apoptotic and 
vasodilator action possibly due to bradykinin release [55]. Recently 
AT4 receptors were identified by molecular cloning [57]; they have 
a very low affinity for AngII and AT1 and AT2 receptor antago-
nists, but they might mediate many physiological functions related 
to cognition, cardiovascular and renal metabolism, and are impli-
cated in diabetes and hypertension [57].  
 AT receptor distribution and mutual balance in tissues and or-
gans are also crucial. In kidneys, their subtypes are not equally 
represented [58]. AT1 receptors are the principal receptors in renal 
vessels and mesangium and, in fact, they are particularly involved 
in renal vessels vasoconstriction as well as mesangial cells contrac-
tion. On the other hand, AT2 receptor stimulation produces sodium 
excretion, increases renal blood flow and attenuates tissue inflam-
mation [59].  
 Recent evidence has shown the existence of a “tissue” renin 
Angiotensin system in which local AngII biosynthesis may be acti-
vated by Renin and/or Angiotensinogen taken up from bloodstream 
[60]. This tissue system is responsible for the vascular and cardiac 
remodeling action of RAAS and of main the intrarenal dynamics.  
 Moreover, other AngI and II metabolites (AngIII and IV) could 
have tissue activity and new findings about ACE2 pathways and its 
products, Ang-1-7 and Ang-1-9 have been reported. These two 
vasoactive peptides act through the Mas receptor (MasR) and 
AT2R, respectively. The ACE2/Ang-1-7/MasR and ACE2/Ang-1-
9/AT2R axes have opposite effects to those of the ACE/Ang 
II/AT1R axis, such as decreased proliferation, reduced cardiovascu-
lar remodeling, increased production of nitric oxide and vasodilata-
tion [61]. These discoveries could give a boost to the newest phar-
macological perspectives also in ARAS and IN [62]. 
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 Before the introduction of ACE-Is in renovascular disease man-
agement, less than half of patients achieved a satisfactory blood 
pressure control, despite multidrug therapy, leading even to the 
necessity of performing rescue bilateral nephrectomy in the drug 
unresponsive patients [63]. Available medications were mostly 
sympatholytic or vasodilator agents, beta-blockers and diuretics, 
which could not counteract the pathophysiological mechanisms 
underlying the elevated blood pressure [20]. Today, between 80 and 
100% of renovascular hypertension patients achieve a target blood 
pressure using drugs acting on RAAS. The first discovered and 
tested ACE-I in renovascular hypertension was Saralasin. Since 
then, several studies on both animal models and humans have 
shown the positive effect of RAAS blockade to limit hemodynamic 
mechanisms central to the hypertension of ARAS and its conse-
quences [64]. Furthermore, the non-hemodynamic effects of ACE-
Is on endothelial function, vascular remodeling and neuro-hormonal 
activation have been discovered in a variety of clinical setting, 
clarifying the mechanisms underlying their cardio-protective and 
renoprotective power [10, 65]. In CKD populations, many con-
trolled clinical trials and RCTs have highlighted the positive effect 
of ACE-I/ARB treatment, not only due to their antihypertensive 
effects but also to their anti-proteinuric activity that provides a sig-
nificant renoprotection [41]. Nevertheless the use of this class of 
drugs in ARAS has always raised concerns, mainly because the 
blockade of RAAS in patients with hemodynamically significant 
stenosis, in some cases, leads to an acute deterioration in renal func-
tion. This is usually caused by the reduction in glomerular blood 
flow reserve that, in absence of anti-Angiotensin drugs, is main-
tained almost exclusively by AngII-induced efferent vasoconstric-
tion [66].  
 Despite this, large RCTs reported that only fifty percent of pa-
tients with IN experience a mild and reversible decline in GFR after 
few days of therapy with ACE-Is, while greater and persistent de-
cline GFR decline occurred in five to ten percent of treated sub-
jects. Indeed, ACE-I induced decline in GFR is almost absent in the 
case of unilateral stenosis with normal contra-lateral kidney blood 
flow [67]. ACE-I-induced renal dysfunction has also been described 
in some patients with nephrosclerosis and normal main renal arter-
ies [13]. Therefore it is not justified to avoid the use of RAAS in-
hibitors in ARAS in the absence of significant negative effects on 
renal function.  
ACE-I PHARMACOLOGY 
 ACE-Is can be classified into three categories based on chemi-
cal structure: those containing a sulfhydryl group similar to Capto-
pril (Fentropril, Peralotril, Zofenopril, Alacepril); those containing 
a carboxyl group similar to Enalapril (Lisinopril, Benazepril, 
Quinapril, Maexipril, Ramipril, Spirapril, Perindopril, Indolapril, 
Pentopril, Enalapril, Cilazapril) and those containing a phosphorus 
group related to Fosinopril [68]. Although acting in the same way, 
not all ACE-Is are equally helpful in all clinical settings [69]. The 
difference among various molecules depends on their chemical 
structure and therefore on their potency, bioavailability, plasma 
half-life, distribution and affinity for tissue-bound ACE. Mecha-
nisms become even more complex in a context like IN in which the 
renal hemodynamic and metabolic responses are modified. Factors 
complicating ACE-Is pharmacology are: 1) the presence of two 
binding sites for ACE-I drugs with different binding constants and 
catalytic substrate selectivity [70]; 2) the extremely high ACE en-
zyme affinity for its inhibitors [71]; 3) almost all ACE-Is are ad-
ministered orally, but the characteristics of all active and inactive 
metabolites are little known; 4) almost 90% of ACE-Is pharmacol-
ogical effects depends on the binding with tissutal enzymes. In 
general ACE-Is work by blocking the activity of ACE and kininase 
II, preventing the conversion of AngI to AngII thus reducing circu-
lating and local levels of AngII. ACE-Is also decrease Aldosterone 
and vasopressin secretion and sympathetic nerve activity, but there 
is controversy regarding their efficacy in blocking other “tissue” 
actions of the RAAS [72-74]. Moreover ACE is a dipeptidyl car-
boxyl metallopeptidase found in tissues and in circulation and lo-
cated at the center of two main antagonistic blood pressure regula-
tory systems: the RAAS and the bradykinin system.  
 Bradykinin system regulates smooth muscle contraction and 
increases vascular permeability and vasodilation. Bradykinin also 
causes natriuresis through direct tubular effects [75].  
 As already mentioned, ACE-Is are a heterogeneous class drug 
as summarized in Table 1 [76]. Regarding to half-life, the shortest 
one is Captopril, while most parts have a long half life of around 
10-12 hours. Except for Fosinopril, elimination is predominantly 
renal, thus a dose adjustment is required in patients with impaired 
renal function. The majority of ACE-Is are prodrugs that remain 
inactive until esterified in the liver. These prodrugs have enhanced 
oral bioavailability compared with their active drugs [68]. For ex-
ample, Ramipril, the most widely used, administered at a single 
dose ranging from 2.5 mg to 20 mg inhibits ACE activation by 60-
80% in four hours and this effect still lasts by 40-60% after 24 
hours. If we administer multiple (14 days) doses of few amounts of 
Ramipril (5.0 mg once daily), ACE activation will be inhibited until 
90% after four hours and 80 % after 24 hours. This effect is related 
to saturation of ACE enzyme binding sites and contemporaneous 
slowed enzymatic release [77]. However the pharmacodynamics of 
ACE-Is cannot be evaluated just by considering its ability to inhibit 
the activity of sieric ACE enzyme. Importantly, the in vitro ability 
of various ACE-Is to bind ACE in different homogenized tissues 
varies depending on the molecule. Therefore, we should take into 
account the ability of the different molecules to bind tissutal ACE. 
Fabris et al., analyzed the binding of various ACE-Is to heart ho-
mogenates and found the following order of potency: quinaprilat = 
benazaprilat > perindoprilat > lisinoprilat > fosinoprilat. The clini-
cal relevance of this observation is still undefined [78]. Considering 
previous pathophysiological findings about the relative importance 
of cardiovascular and endothelial protection, anti-atherosclerotic 
and antioxidant effects than hemodynamically pressor action, we 
could infer that it is better to choose RAAS blockers molecules with 
greater proven pleiotropic effects profile rather than a pharmacol-
ogical approach [79]. Perindopril and Ramipril have been shown to 
have a longer duration of action, higher lipophilicity, and stronger 
tissue ACE inhibiting properties compared with other ACE-Is, 
These features have made these two drugs the most chosen for CV 
prevention [80]. Even in terms of endothelial protection Perindopril 
and Ramipril have demonstrated the best protection against endo-
thelial apoptosis. In particular, a probable order of potency of ACE-
Is could be Perindopril > Ramipril >> Quinapril = Trandolapril = 
Enalapril, with significant differences between Perindopril and 
Quinapril (P < 0.01), Trandolapril (P < 0.001), and Enalapril (P < 
0.001). Perindopril demonstrated also to have superior anti-
inflammatory properties compared to Enalapril, although, most 
studies and RCTs in ARAS used Enalapril [20]. 
ARBS PHARMACOLOGY  
 ARBs were synthesized as a newer RAAS-modulating class of 
antihypertensive agents [81]. They reduce blood pressure by block-
ing AngII–induced vasoconstriction and decreasing catecholamine, 
Aldosterone and Vasopressin release. Simultaneously ARBs blunt 
salt and water intake [82]. These substances differ from ACE-Is 
since they selectively inhibit AngII effects antagonizing AT1 [83]. 
Ang II is produced not only by ACE, but also by many other enzy-
matic non-renin pathways, such as tonin or cathepsin, trypsin and 
chymase [84]. Therefore ARBs, by directly and more specifically 
inhibiting AT1 may have a more targeted pharmacological action. 
The US Food and Drug Administration approved seven of them for 
hypertension treatment; Losartan, Candesartan, Valsartan, Olmesar-
tan, Irbeesartan, Telmisartan, Eprosartan [86]. Main pharmacologic 
features are outlined in Table 1.  
4    Current Drug Metabolism, 2016, Vol. 17, No. 5 Rivoli et al. 
Table 1. 
ACE-Is 
Mechanism of action: Block the activity of ACE (or kininase II), decrease Aldosterone and vasopressin secretion and sympathetic nervous activity 
Indications: Treatment of hypertension and heart failure, delay in progression of chronic non-diabetic and diabetic renal disease, renovascular dis-
ease management 
Main common side effects: Increase risk of angioedema, hypotension, cough, AKI, hyperkaliemia 
 
 Half life 
(h) 
T max 
(h) 
Renal elimination 
(%) 
ARAS/IN trial Doses used in 
major trials (mg) 
Dose range 
(mg) 
Captopril 2 1-2 80% Hollenberg et al 100-150 25-150 
Enalapril 2-6 1 60% Franklin et al., 
Hodsman et al., 
Reams et al. 
20-40 10-40 
Fosinopril 12 1-3 50% NR  20-40 
Benazepril 10-11 1-2 90% NR 30 20-40 
Lisinopril 12 6 100% NR  20-40 
Ramipril 13-17 1 60% Tillman et al. 10 2,5-20 
Perindopril 1,5-3 1-2 75% NR 4 4-8 
ARBs 
Mechanism of action: Block AT1 receptors activity 
Indications: Treatment of hypertension and heart failure, delay in progression of chronic non-diabetic and diabetic renal disease, renovascular disease 
management 
Main common side effects: Increase risk of hypotension, AKI, hyperkaliemia 
 
 Half life 
(h) 
T max 
(h) 
Renal elimination 
(%) 
ARAS/IN trial Doses used in 
major trials 
(mg/dL) 
Dose range 
(mg/dL) 
Losartan 6-9 3-4 35 NR 100 50-100 
Valsartan 6-9 2-4 10 NR 160 80-320 
Olmesartan 13 1-3 8-10 NR  20-40 
Candesartan 5-9 3-4 33 CORAL 16 16-32 
Irbesartan 11-15 1,5-2 20 NR 300 150-300 
Telmisartan 24 0,5-1 ~0 NR  40-80 
Eprosartan 5-9 1-2 7 NR  400-800 
DRIs 
Mechanism of action: Direct Renin inhibition 
Indications: Treatment of hypertension  
Main common side effects: Increase risk of hypotension, AKI, hyperkaliemia, angioedema 
 
 Half life 
(h) 
T max 
(h) 
Renal elimination 
(%) 
ARAS/IN trial Doses used in 
major trials 
(mg/dL) 
Dose range 
(mg/dL) 
Aliskiren 24 1-3 25 NR 100 150-300 
 
 Similarly to ACE-Is, ARBs display different pharmacokinetic 
profiles, which may explain potential effectiveness difference [83]. 
The power of each specific molecule depends on three parameters: 
pressure inhibition, AT1 selectivity/affinity and half-life. Food and 
Drug Administration (FDA) provides in the technical sheets the 
differences between ARBs based on these three criteria, helping 
clinicians choosing the most appropriate drug in different settings 
of disease. Irbesartan, Candesartan, Telmisartan, and Olmesartan 
show a longer half-lives and duration of action than Losartan and 
Valsartan. 24-hour blood pressure can be better controlled by newer 
agents (Irbesartan, Candesartan, Telmisartan, and Olmesartan). 
Older ones (Losartan and Valsartan) may need twice daily admini-
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stration. Losartan’s major active metabolite, EXP- 3174, is 10 to 20 
times more potent than Losartan and has a longer duration of ac-
tion. EXP- 3174 is the only responsible for the therapeutic effects. 
Candesartan and Olmesartan are pro-drugs; they are subjected to 
metabolic activation during absorption from the gastrointestinal 
tract. The parent compounds of Candesartan and Olmesartan have 
lower efficacy. Once Olmesartan is rapidly converted to its active 
metabolite, it is not subjected to further metabolism. Losartan, Can-
desartan, and Eprosartan have short half-lives so they require twice-
daily dosing in some patients [85-87]. ARBs clearance is much less 
dependent on renal elimination than ACE-Is and this might repre-
sent a vantage in chronic IN patients. Beyond pharmacokinetic 
differences, molecular variance could lend pharmacodynamic pro-
prieties and thus different pleiotropic actions between ARBs. At 
this regard difference becomes more evident if considering newer 
or older generation ARBs [88, 89]. In contrast to ACE-Is, ARBs do 
not enhance concentrations of bradykinin, a stimulus for NO re-
lease; but they may enhance eNOS expression and this propriety 
could vary between different ARBs molecules [90]. Olmesartan, as 
compared to Losartan, Valsatan and Telmisartan, has the most 
beneficial effect on endothelial function and nitric oxide release. 
The presence of the hydroxyl group may contribute to free radical 
scavenging properties for Olmesartan, including chain-breaking 
antioxidant activity [91]. ARBs have been shown to decrease 
plaque grow in ApoE-deficient mouse model of atherosclerosis 
[92]. In a mouse model of renovascular hypertension Losartan 
demonstrated to prevent oxidative stress generation and may at-
tenuate kidney oxidative injury [93]. As for ACE-Is, AKI cases 
were reported in bilateral renal artery stenosis or in solitary kidney 
[94, 95]. However, ARBs clearly-demonstrated efficacy and safety, 
fully justifies their use in unilateral renovascular disease. There are 
no clinical studies comparing the different molecules in renovascu-
lar disease setting, although in the CORAL trial has been employed 
Candesartan. 
CLINICAL ASPECTS OF RAAS BLOCKADE IN ARAS AND 
IN  
 Detailed clinical evidence about RAAS modulators effective-
ness in chronic IN is still lacking. This may be related to the afore-
mentioned preoccupations raised by GFR reduction induced, in 
some cases, by this drug class. Currently, most RCTs enrolled mild-
moderate ARAS subjects and/or excluding those with moderate to 
severe kidney dysfunction. Indeed, large trials, comparing the effi-
cacy of different RAAS blocking agents classes and molecules, 
have not yet been published for IN. Consequently, our current 
knowledge about the safety and efficacy of RAAS inhibitors in 
chronic renal ischemia should be derived by from studies in ARAS 
and renovascular hypertension in patients with CKD.  
 In 1963, Dustan et al, performed the first trial exploring the 
medical management of renovascular hypertension. In this study 
conservative therapy consisted in a combination of three drugs (hy-
dralazine, guanethidine, and a thiazide diuretic) chosen as an alter-
native to interventional approach in 32 subjects in which surgery 
was contraindicated for various reasons [96]. Of course, RAAS 
inhibitors could not be included and only less than a half of patients 
achieved a stable blood pressure and creatinine control. Neverthe-
less the authors suggested that medical approach could be a valid 
option in case of impracticable interventional management. After-
wards, many studies showed the efficacy of ACE-Is and ARBs in 
reducing blood pressure, cardiovascular risk and progression to 
ESRD, compared to other antihypertensive agents in different dis-
eases [97, 98]. Many papers emphasized their direct nephroprotec-
tive ability as already mentioned in previous paragraphs. The first 
study describing the use of an ACE-I, Captopril, in renovascular 
hypertension was published in 1983 by Hollenberg et al. [99]. This 
retrospective multicentre analysis enrolled 269 atherosclerotic 
renovascular disease patients, including bilateral renal artery and 
solitary kidney stenosis. Half of them had a baseline serum creatin-
ine up to 1.5 mg/dl and 74% of patients achieved the blood pressure 
target [99]. This trial did not reported about effect on kidney func-
tion, so that we can argue that they were not relevant. Subsequently, 
other studies compared ACE-Is, primarily Enalapril and/or Enala-
pril plus hydrochlorothiazide versus standard triple therapy [100-
102]. 
 Franklin et al., considered renal function as a safety outcome 
documenting an acute decline in renal function in 10 out of 75 sub-
jects. Then, important observational studies by Tullis et al. in 1999, 
Losito et al. in 2005 and Hackman et al. in 2008 reviewed the effi-
cacy of ACE-Is in ARAS, demonstrating that patients treated with 
ACE-Is exhibited a better long-term blood pressure control, even 
after revascularization. Furthermore, Hackman and colleagues 
found that therapy with ACE-Is was associated with a significantly 
lower risk of death for cardiovascular events and, remarkably, for 
maintenance dialysis initiation. In this large report, authors high-
lighted that, despite being at greater risk of developing AKI, pa-
tients who were treated with RAAS inhibitors for renovascular 
disease, had a significantly reduced incidence of requiring long-
term haemodialysis. Therefore they concluded that the higher inci-
dence of acute and in most-cases reversible renal dysfunction does 
not justify the choice of avoiding RAAS blockage in these patients. 
Besides, the AKI risk was well balanced by the renoprotective and 
overall cardioprotective effect. Unfortunately in all these papers 
there are no indications about the molecule and/or dosage applied.  
 After the introduction of percutaneous revascularization tech-
niques, large multicenter trials like “Angioplasty and Stenting for 
Renal Artery Lesions” (ASTRAL), “Stent placement in patients 
with atherosclerotic renal artery stenosis” (STAR) and “The Car-
diovascular Outcomes in Renal Atherosclerotic Lesions” (CORAL) 
mainly focused on comparing medical management versus inter-
ventional approaches. ACE-Is or ARBs were always part of the 
drug regimen and were apparently well tolerated [14].  
 In ASTRAL both interventional and medical groups had a 50% 
rate of patients treated with RAAS blocking drugs. However, drug 
preparation and dosage were locally established and not reported in 
the paper [15]. 
 In 2009 the STAR trial was the first published study accounting 
renal protection as primary end point in ARAS patients under 
medical management versus PTRA. All patients were affected by 
impaired renal function (GFR < 80 mL/min per 1.73 m2). The 
authors did not find any difference between invasive and conserva-
tive therapy, even after 2 years of follow-up. Furthermore this paper 
highlighted the advantage in this CKD-ARAS population of a mul-
tilevel integrated medical intervention consisted in the contempo-
rary use of antihypertensive, lipid-lowering agents, antiplatelet and 
smoking cessation. Unfortunately they did not focus on RAAS 
blockade effect and drug preparation and dosage were not reported. 
 The more recent CORAL trial introduced the concept of “Op-
timal medical therapy” for renovascular disease patients. The re-
sults from this RCT further reduced enthusiasm of PTRA as an 
intervention for ARAS and were not without controversy. Possible 
explanations for this observed lack of benefit of PTRA include 
suboptimal selection of an appropriate population for which inter-
ventional approach was performed. It is already clear that patients 
who might benefit from revascularization are only those in which 
there is not irreversible kidney dysfunction. While patients affected 
by IN may not have an advantage from hemodynamic recovery, but 
they benefit of an integrated and well-structured medical approach. 
 “Optimal medical therapy” consisted of the combination of a 
multilevel cardiovascular risk factors correction. It includes smok-
ing cessation, antiplatelet therapy and other protocol-driven medical 
therapies to control blood pressure, glucose and lipid levels in ac-
cordance with guidelines. Candesartan, with or without hydro-
chlorothiazide is the most studied drug in renovascular conditions. 
It should be administered together with ca-antagonist and statins 
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(amlodipine–atorvastatin) to reach the maximum efficacy. The dose 
should be adjusted on the basis of blood pressure and lipid status. 
Candesartan might be replaced by ACE-Is in ARBs intolerant pa-
tients. 
 A major concern for using antiangiotensin drugs is their safety 
in patients with CKD In 2014, Evans et al., published a review 
based on CORAL’s data disclosing that, even today, there is a very 
strong uncertainty on RAAS blockers prescription especially among 
IN patients. Clinicians do not yet seem convinced about safety and 
efficacy of this class as first choice therapy [17]. Often they are 
discouraged by the slight and mostly reversible creatinine increase 
that might appear during first weeks of treatment. Although these 
drugs have been safely used in many patients with serum creatinine 
levels up to 4 mg/dl with and without diabetes, with no significant 
onset of side effect such us AKI or hyperkalaemia, a common prac-
tice is to interrupt RAAS blocking agents when serum creatinine 
rises above 20-30% from baseline [103].  
 As yet, no clear guidelines on pharmacological therapeutic 
management of patients affected by ARAS and information about 
levels of renal dysfunction for RAAS blockers discontinuation have 
been published. Some authorities recommend monitoring serum 
creatinine levels and blood pressure every 3 months and non-
invasive imaging of kidney (eg, using renal ultrasound and duplex 
scanning of the renal artery) to assess renal size and progression of 
stenotic lesions every 6-12 months.  
 Other studies suggest nuclear imaging because it can provide an 
estimate of blood flow and GFR for each kidney. This test could be 
useful in patients with normal renal function at baseline when the 
serum creatinine level alone cannot represent a sensitive indicator 
of progressive renovascular disease [13].  
CONCLUSIONS 
 Optimal medical management of patients with renovascular 
disease and IN should be primarily directed to controlling BP and 
preservation of kidney function. IN must be treated as the CKD 
equivalent of coronary artery disease, focusing on rigorous man-
agement of hypertension, hyperglycemia, and hyperlipidemia. Life-
style modifications, such as cessation of smoking, and antiplatelet 
therapy have reduced the risk of cardiovascular events in high-risk 
patients. Antihypertensive treatment should include RAAS block-
ade medication not only for their antihypertensive properties, but 
especially for those cardio and renoprotective. 
 More well designed RCTs are needed to comprehend which 
patients could better benefit of medical therapy and how chose the 
molecule and personalize the dosage. An optimal pharmacologic 
approach is crucial for a successful prevention of renal injury and 
cardiovascular events in this high-risk population.  
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